


# Biotech hot spots in a fragmented European landscape

Mapping ~1,000 European biotechs by country, modality, and therapeutic area reveals 8 clusters



Share of landscape, %



## Geographies: 2 speeds

Total investment has increased over past 7 years **2.3x** compared with previous 7 years

	Before 2012	Since 2012
United Kingdom	23%	35%
Switzerland	7%	9%
Netherlands	6%	8%
Belgium	3%	5%

	Before 2012	Since 2012
France	12%	10%
Germany	11%	7%
Israel	9%	7%
Sweden	10%	5%

## Top therapeutic modalities (new biotechs)



Modality focus of new companies founded 2012–18, % of total

Diagnostics	22%
Drug-discovery tools and services	20%
Immunotherapies	16%
Cell and gene therapies	13%

**29%** of new biotechs since 2012 have focused on immunotherapies and cell and gene therapies

## Top therapeutic areas (new biotechs)

Therapeutic-area focus of new companies founded 2012–18, % of total



¹ All other companies—not counted as a cluster.

Sources: BCIQ, BioCentury, February/March 2019, biocentury.com; Pharmaprojects, Informa, 2019, pharmaintelligence.informa.com; PitchBook, PitchBook Data, February 2019, pitchbook.com; McKinsey analysis